Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18411750 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | January 2024 | April 2024 | Allow | 3 | 1 | 0 | No | No |
| 18495278 | RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of Use | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18246845 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | March 2023 | April 2024 | Allow | 13 | 1 | 0 | No | No |
| 18176174 | METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION | February 2023 | August 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18171539 | Modulators of PCSK9 Expression | February 2023 | August 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17990757 | COMPOSITION FOR PREVENTING OR TREATING KELOIDS OR HYPERTROPHIC SCARS | November 2022 | December 2023 | Allow | 12 | 0 | 0 | No | No |
| 18055823 | GENE EDITING FOR HEMOPHILIA A WITH IMPROVED FACTOR VIII EXPRESSION | November 2022 | January 2024 | Allow | 14 | 0 | 0 | No | No |
| 18053195 | NUCLEIC ACID OLIGOMERS AND USES THEREFOR | November 2022 | October 2023 | Allow | 11 | 0 | 0 | No | No |
| 17937617 | GENETIC ELEMENTS DRIVING CIRCULAR RNA TRANSLATION AND METHODS OF USE | October 2022 | February 2023 | Allow | 4 | 0 | 0 | No | No |
| 17929704 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | September 2022 | December 2022 | Allow | 3 | 1 | 0 | No | No |
| 17820425 | GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) | August 2022 | August 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17819691 | COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | August 2022 | February 2024 | Abandon | 18 | 0 | 1 | No | No |
| 17881193 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | August 2022 | April 2024 | Allow | 21 | 1 | 1 | No | No |
| 17872504 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | July 2022 | August 2023 | Allow | 13 | 1 | 0 | Yes | No |
| 17847550 | MODIFIED DOUBLE-STRANDED RNA AGENTS | June 2022 | October 2022 | Allow | 4 | 1 | 0 | No | No |
| 17808247 | PIKFYVE ANTISENSE OLIGONUCLEOTIDES | June 2022 | May 2024 | Allow | 23 | 1 | 1 | No | No |
| 17846518 | MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes | June 2022 | January 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17846794 | REDUCING INTRON RETENTION | June 2022 | September 2023 | Allow | 15 | 0 | 0 | Yes | No |
| 17839699 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | June 2022 | January 2023 | Allow | 7 | 1 | 0 | No | No |
| 17836458 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | June 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17834611 | STRATEGY TO INCREASE ANTI-VIRAL, ANTI-MICROBIAL, AND ANTI-FUNGAL DEFENSE | June 2022 | October 2023 | Allow | 16 | 0 | 0 | No | No |
| 17752106 | Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy | May 2022 | January 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17741758 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | May 2022 | February 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17733552 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | April 2022 | January 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17715815 | INHIBITION OF NUCLEIC ACID POLYMERASES BY ENDONUCLEASE V-CLEAVABLE CIRCULAR OLIGONUCLEOTIDE LIGANDS | April 2022 | January 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 17711911 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | April 2022 | May 2022 | Allow | 2 | 0 | 0 | No | No |
| 17709965 | HSD17B13 Variants And Uses Thereof | March 2022 | April 2023 | Allow | 13 | 1 | 1 | No | No |
| 17705166 | ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER STEM CELLS | March 2022 | January 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17701238 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | March 2022 | October 2023 | Allow | 19 | 0 | 1 | No | No |
| 17697405 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | March 2022 | March 2024 | Allow | 24 | 1 | 1 | No | No |
| 17696606 | GENETIC ELEMENTS DRIVING CIRCULAR RNA TRANSLATION AND METHODS OF USE | March 2022 | September 2022 | Allow | 6 | 0 | 1 | No | No |
| 17694982 | THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR CANCER INCLUDING MIRNA | March 2022 | April 2024 | Allow | 26 | 2 | 0 | No | No |
| 17695079 | THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR CANCER INCLUDING MIRNA | March 2022 | April 2024 | Allow | 25 | 2 | 0 | No | No |
| 17694210 | GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) | March 2022 | May 2022 | Allow | 2 | 0 | 0 | No | No |
| 17678792 | Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors | February 2022 | August 2023 | Allow | 18 | 1 | 1 | No | No |
| 17667988 | NUCLEIC ACID COMPOUND AND OLIGONUCLEOTIDE | February 2022 | October 2023 | Allow | 20 | 2 | 0 | No | No |
| 17667449 | ANGPTL4 OLIGONUCLEOTIDES INFLUENCING THE REGULATION OF THE FATTY ACID METABOLISM | February 2022 | June 2023 | Allow | 16 | 2 | 0 | Yes | No |
| 17576130 | RAAV-BASED COMPOSITIONS AND METHODS | January 2022 | October 2023 | Allow | 21 | 1 | 0 | No | No |
| 17572615 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | January 2022 | June 2022 | Allow | 5 | 1 | 1 | No | No |
| 17567482 | PARTICLE-MEDIATED DELIVERY OF BIOLOGICS | January 2022 | March 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17561095 | MODULATION OF GYS1 EXPRESSION | December 2021 | March 2023 | Allow | 14 | 0 | 0 | No | No |
| 17555285 | NANOPARTICLE TO TARGET CANCER | December 2021 | February 2023 | Allow | 14 | 0 | 0 | No | No |
| 17536880 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER | November 2021 | April 2024 | Allow | 28 | 2 | 1 | No | No |
| 17533825 | Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy | November 2021 | September 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17523240 | MODIFIED DOUBLE-STRANDED RNA AGENTS | November 2021 | March 2022 | Allow | 5 | 1 | 0 | No | No |
| 17453995 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | November 2021 | November 2022 | Allow | 12 | 2 | 0 | Yes | No |
| 17515859 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | November 2021 | July 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17511022 | GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) | October 2021 | March 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17510277 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | October 2021 | October 2023 | Allow | 24 | 1 | 0 | No | No |
| 17508379 | INHIBITION OF NUCLEIC ACID POLYMERASES BY ENDONUCLEASE V-CLEAVABLE OLIGONUCLEOTIDE LIGANDS | October 2021 | August 2023 | Allow | 21 | 1 | 0 | No | No |
| 17506012 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CHRONIC DISEASE | October 2021 | October 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17479617 | MODIFIED DOUBLE-STRANDED RNA AGENTS | September 2021 | January 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17477456 | COMPOSITIONS COMPRISING RIBOREGULATORS AND METHODS OF USE THEREOF | September 2021 | May 2023 | Allow | 20 | 0 | 0 | No | No |
| 17475305 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | September 2021 | September 2023 | Allow | 24 | 1 | 1 | No | No |
| 17474264 | Methods for Treatment of Alport Syndrome | September 2021 | December 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17473863 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | September 2021 | January 2022 | Allow | 4 | 0 | 0 | No | No |
| 17467390 | CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy | September 2021 | September 2023 | Allow | 24 | 1 | 1 | No | No |
| 17459213 | INHIBITION OF EXPANSION AND FUNCTION OF PATHOGENIC AGE-ASSOCIATED B CELLS AND USE FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASE | August 2021 | August 2023 | Allow | 24 | 1 | 1 | No | No |
| 17410504 | HELIX 73-DERIVED RNA MOLECULES INTERACTING WITH ERM PROTEIN AND METHODS OF USING THE SAME | August 2021 | February 2024 | Allow | 30 | 1 | 1 | No | No |
| 17407930 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | August 2021 | May 2022 | Allow | 9 | 1 | 1 | No | No |
| 17407966 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | August 2021 | April 2022 | Allow | 8 | 2 | 0 | Yes | No |
| 17406718 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | August 2021 | December 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17395683 | METHOD OF DELIVERING GENES AND DRUGS TO A POSTERIOR SEGMENT OF AN EYE | August 2021 | June 2023 | Allow | 22 | 1 | 0 | No | No |
| 17378528 | ANTISENSE OLIGOMERS TARGETING PCSK9 | July 2021 | March 2023 | Allow | 20 | 1 | 0 | No | No |
| 17341057 | EXOSOMES AND MIRNA TO TREAT GLAUCOMA | June 2021 | July 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17339142 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | June 2021 | January 2022 | Allow | 7 | 0 | 1 | No | No |
| 17324944 | MOLECULAR FUSES FOR REAL-TIME, LABEL-FREE, MULTIPLEXED IMAGING OF RNAs IN LIVING CELLS | May 2021 | June 2023 | Allow | 25 | 1 | 0 | No | No |
| 17293356 | ANGPTL4 OLIGONUCLEOTIDES INFLUENCING THE REGULATION OF THE FATTY ACID METABOLISM | May 2021 | February 2024 | Allow | 33 | 2 | 1 | No | No |
| 17315939 | TREATMENT OF TUMORS WITH MIRNA TARGETING CDK4/CDK6 | May 2021 | August 2023 | Allow | 27 | 1 | 1 | No | No |
| 17231409 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | April 2021 | January 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17231969 | ANTISENSE-INDUCED EXON EXCLUSION IN MYOSTATIN | April 2021 | June 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17227802 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | April 2021 | August 2021 | Allow | 4 | 1 | 0 | Yes | No |
| 17225788 | GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) | April 2021 | July 2021 | Allow | 3 | 0 | 0 | No | No |
| 17218682 | TREATMENTS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | March 2021 | July 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17217989 | PHOSPHOROTHIOATE-CONJUGATED miRNAs AND METHODS OF USING THE SAME | March 2021 | August 2023 | Allow | 29 | 2 | 0 | No | No |
| 17193182 | TRANSPOSON-BASED TRANSFECTION SYSTEM FOR PRIMARY CELLS | March 2021 | December 2023 | Allow | 34 | 1 | 1 | No | No |
| 17191895 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | March 2021 | August 2021 | Allow | 6 | 0 | 1 | Yes | No |
| 17185587 | PROCESSES OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | February 2021 | December 2023 | Allow | 33 | 1 | 1 | No | No |
| 17182423 | POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF | February 2021 | September 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17170047 | Novel Structurally Designed shRNAs | February 2021 | April 2023 | Allow | 26 | 1 | 0 | No | No |
| 17158845 | METHODS AND COMPOSITIONS FOR MODULATING LNCRNAS AND METHODS OF TREATMENT BASED ON LNCRNA EXPRESSION | January 2021 | February 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17050148 | SCREENING METHOD FOR THERAPEUTIC SUBSTANCE FOR PREVENTING OR TREATING BRONCHOPULMONARY DYSPLASIA (BPD) | January 2021 | May 2024 | Allow | 43 | 1 | 0 | No | No |
| 17150934 | RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | January 2021 | April 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17146554 | COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | January 2021 | May 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17146147 | VON WILLEBRAND FACTOR (VWF)-TARGETING AGENTS AND METHODS OF USING THE SAME | January 2021 | December 2023 | Allow | 35 | 1 | 1 | No | No |
| 17141275 | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | January 2021 | April 2024 | Allow | 39 | 2 | 1 | No | No |
| 17126330 | Oligonucleotides Comprising Modified Nucleosides | December 2020 | October 2022 | Allow | 22 | 0 | 0 | No | No |
| 17125053 | SEXUAL MATURATION IN RAINBOW TROUT | December 2020 | May 2024 | Allow | 40 | 1 | 1 | No | No |
| 17121885 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | December 2020 | October 2023 | Abandon | 34 | 1 | 1 | No | No |
| 17114210 | PANCREATIC CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | December 2020 | June 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17105174 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | November 2020 | September 2023 | Abandon | 34 | 1 | 1 | Yes | No |
| 17103671 | MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN | November 2020 | March 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17102500 | POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF | November 2020 | February 2023 | Abandon | 27 | 0 | 1 | No | No |
| 16953704 | Modulators of PCSK9 Expression | November 2020 | November 2022 | Allow | 24 | 1 | 0 | No | No |
| 17056203 | tRNA/pre-miRNA Compositions and Use in Treating Cancer | November 2020 | September 2023 | Allow | 34 | 2 | 1 | No | No |
| 17099503 | Increasing Specificity for RNA-Guided Genome Editing | November 2020 | October 2023 | Allow | 35 | 1 | 1 | No | No |
| 17055812 | MITOCHONDRIAL OPTOGENETICS-BASED GENE THERAPY FOR TREATING CANCER | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17095945 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | November 2020 | January 2023 | Allow | 26 | 0 | 1 | No | No |
| 17092435 | POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF | November 2020 | February 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17093038 | RNA NANOPARTICLES AND METHOD OF USE THEREOF | November 2020 | August 2023 | Allow | 33 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUDSON, AMY ROSE.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HUDSON, AMY ROSE works in Art Unit 1635 and has examined 938 patent applications in our dataset. With an allowance rate of 59.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 26 months.
Examiner HUDSON, AMY ROSE's allowance rate of 59.4% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HUDSON, AMY ROSE receive 1.49 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HUDSON, AMY ROSE is 26 months. This places the examiner in the 60% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +21.0% benefit to allowance rate for applications examined by HUDSON, AMY ROSE. This interview benefit is in the 69% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 25.8% of applications are subsequently allowed. This success rate is in the 32% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 60.2% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 88.9% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 60.0% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.3% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 47% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.